RADNOR,
Pa., June 20, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that Stephen Willard,
J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx
Pharmaceuticals, will present a company overview at the H.C.
Wainwright 4th Annual Neuropsychiatry Virtual Conference. The
presentation will be available for live viewing on Monday, June 26, 2023 at 9:00 a.m. ET. Management will be available
for one-on-one meetings with conference attendees as well.
A webcast and subsequent archived replay will be available on
the Company's website at
https://ir.nrxpharma.com/news-events/ir-calendar. The replay will
be available for 90 days after the event.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical -stage biopharmaceutical
company developing therapeutics for the treatment of central
nervous system disorders, specifically bipolar depression with
suicidality and post-traumatic stress disorder (PTSD). The
company's lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's
N-methyl-D-aspartate (NMDA) receptor and is being investigated in a
Phase 2b/3 clinical trial for
Suicidal Treatment-Resistant Bipolar Depression, which includes
patients with both acute and sub-acute suicidality, an indication
for which the only approved treatment is electroshock therapy. The
company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101
in patients with Severe Bipolar Depression with Acute Suicidal
Ideation & Behavior (ASIB) demonstrated a substantial
improvement over available therapy in reducing depression and
suicidality compared to placebo when patients were treated with
NRX-101 after a single dose of ketamine. Based on the findings from
the STABIL-B trial, the U.S. Food and Drug Administration (FDA)
granted a Special Protocol Agreement and Breakthrough Therapy
Designation for NRX-101 in patients with Severe Bipolar Depression
with ASIB.
View original
content:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-present-at-the-hc-wainwright-4th-annual-neuropsychiatry-virtual-conference-301855874.html
SOURCE NRx Pharmaceuticals, Inc.